Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alveolar bone augmentation using mesenchymal stem cells and biphasic calcium phosphate
2018-004046-41Phase 2Active
- Sponsor
- University of Bergen
- Start
- Dec 2021
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous bone marrow derived mesenchymal stromal cells in Alveolar bone atrophy (ABL) and partial edentulism, sponsored by University of Bergen. Primary endpoint: New bone formation and readiness for implant placement at 5–6 months. Started Dec 2021; status: active.
02
Drugs
autologous bone marrow derived mesenchymal stromal cells
03
Conditions
Alveolar bone atrophy (ABL)partial edentulism
Beyond the preview
Go deeper on 2018-004046-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004046-41.